The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | Biomarkers to predict outcomes in patients with myeloma treated with lenalidomide and dexamethasone
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, comments on the results of a study investigating biomarkers to predict response and resistance to lenalidomide-dexamethasone in elderly patients with multiple myeloma. In this study, patients were randomized to receive lenalidomide and dexamethasone with or without clarithromycin. The study was able to identify immune cell types associated with progression-free survival (PFS) as well as patients at a high risk of infections. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
